23.11.2015 21:11:00
|
Pfizer Inc. -- Moody's: Pfizer business profile strengthens with Allergan, but likely buybacks are credit negative
New York, November 23, 2015 -- Pfizer's acquisition of Allergan will improve the company's scale, diversity and research pipeline, but will also increase shareholder payouts, lowering the company's cash levels over time, says Moody's Investors Service.